Morgan Stanley Analyzes Amgen's Position Amidst Drug Development Setbacks

Tuesday, September 22, 2026·Consolidated from 2 sources

Morgan Stanley has highlighted a potential advantage for Amgen following setbacks experienced by a rival in the heart drug market. The firm's analysis comes as investor attention turns to Saia, with a discussion around the credibility of its current stock discount.

Morgan Stanley's analysts have pointed to a potential edge for Amgen in the cardiovascular drug space. This assessment comes in the wake of challenges faced by a competitor in developing a heart-related therapy, according to recent coverage.

The financial institution's commentary suggests that the stumbles of a rival could benefit Amgen's market position. While specific details of the rival's setbacks were not elaborated upon, the implication is that this could create opportunities for Amgen's existing or pipeline treatments.

Separately, attention is also being directed towards logistics company Saia. Reports indicate that Saia is scheduled to participate in Morgan Stanley's Laguna Conference. This event provides a platform for the company to discuss its business and outlook with investors and analysts.

Concurrently, discussions are emerging regarding the valuation of Saia's stock. Questions are being raised about whether the current discount, reported to be around 21%, is a credible reflection of the company's intrinsic value or future prospects. The upcoming conference may offer insights to help address these investor queries.

Sources